[1]SHARMA AK,KIM TS,BAUER S,et al.Gastrointestinal stromal tumor:New insights for a multimodal approach[J].Surg Oncol Clin N Am,2022,31(3):431-446.
[2]HUANG WK,WU CE,WANG SY,et al.Systemic therapy for gastrointestinal stromal tumor:Current standards and emerging challenges[J].Curr Treat Options Oncol,2022,23(9):1303-1319.
[3]SERRANO C,GEORGE S.Gastrointestinal stromal tumor:Challenges and opportunities for a new decade[J].Clin Cancer Res,2020,26(19):5078-5085.
[4]BRINCH CM,AGGERHOLM-PEDERSEN N,HOGDALL E,et al.Medical oncological treatment for patients with gastrointestinal stromal tumor(GIST)-A systematic review[J].Crit Rev Oncol Hematol,2022,172:103650.
[5]LI J,GUO S,SUN Z,et al.Noncoding RNAs in drug resistance of gastrointestinal stromal tumor[J].Front Cell Dev Biol,2022,10:808591.
[6]ARSHAD J,COSTA PA,BARRETO-COELHO P,et al.Immunotherapy strategies for gastrointestinal stromal tumor[J].Cancers(Basel),2021,13(14):3525.
[7]TAN Y,TRENT JC,WILKY BA,et al.Current status of immunotherapy for gastrointestinal stromal tumor[J].Cancer Gene Ther,2017,24(3):130-133.
[8]LIAO D,SUNDLOV J,ZHU J,et al.Atomic level dissection of the platelet endothelial cell adhesion molecule 1(PECAM-1) homophilic binding interface:Implications for endothelial cell barrier function[J].Arterioscler Thromb Vasc Biol,2022,42(2):193-204.
[9]SILVA A,PEREIRA SS,BRANDAO JR,et al.Colon tumor CD31 expression is associated with higher disease-free survival in patients with metabolic syndrome[J].Pathol Res Pract,2022,240:154182.
[10]VOCKOVA P,MOLINSKY J,KLANOVA M,et al.CD31/PECAM-1 impacts engraftment,growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement[J].Leuk Lymphoma,2021,62(4):861-867.
[11]BAYIK D,LATHIA JD.Cancer stem cell-immune cell crosstalk in tumour progression[J].Nat Rev Cancer,2021,21(8):526-536.
[12]SUN JH,LUO Q,LIU LL,et al.Liver cancer stem cell markers:Progression and therapeutic implications[J].World J Gastroenterol,2016,22(13):3547-3557.
[13]LIU FC,WANG Q,LI RT.Gastrointestinal stromal tumor:microenvironment characteristics and immunotherapy ideas[J].Chinese Journal of Cancer Biotherapy,2022,29(8):708-713.
[14]LIU Y,ZHANG Z,LI W,et al.PECAM1 combines with CXCR4 to trigger inflammatory cell infiltration and pulpitis progression through activating the NF-kappaB signaling pathway[J].Front Cell Dev Biol,2020,8:593653.
[15]CHEN MZ,YANG H,WANG CH,et al.Expression and significance of PECAM1 in cancer tissues of elderly patients with NSCLC[J].Journal of Clinical Pulmonary Medicine,2019,24(4):614-617.